Across TCGA pan-cancer cohorts, MUS81 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated MUS81 data layer compared with 29 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher MUS81 mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated MUS81 expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.
HNSC and GBM are the cancer types where MUS81 mass-spec protein most reproducibly stratifies survival.